共查询到20条相似文献,搜索用时 62 毫秒
1.
92例原发性Ⅰ和Ⅱ期高血压病人采用随机、单盲方法,分2组治疗。一组用赖诺普利,po,20-80mg/d,另一组用依那普利,po,10-40mg/d,疗程均为4wk。降压总有效率和降压幅度:赖诺普利是89%和2.9/2.0kPa,依那普利是97%和3.1/2.1kPa,2药降压均显著(P<0.01),降压疗效相仿(P>0.05)。不良反应发生率是29%和34%,其中最多是干咳。结果提示赖诺普利治疗轻、中度高血压有效、安全。 相似文献
2.
目的 研究中国人群中原发性高血压患血管紧张素转换酶(ACE)基因多态性及其危险因素的关系。方法 对社区人群调查中确诊的112例原发性高血压患,和相同数量,性别、年龄相的健康人询问与原发性高血压有关的因素,测量空腹血脂及坐位血压,应用聚合酶链反应(PCR)检测ACEI/D基因多态性。结果 两组ACE基因I/D多态性构成有显性差异(P〈0.05)。病例组DD基因型高于对照组(30.4%vs18. 相似文献
3.
赖诺普利对原发性高血压胰岛素敏感性的影响 总被引:2,自引:1,他引:1
目的:观察赖诺普利对原发性高血压(EH)病人胰岛素敏感性的影响。方法:将56例EH病人分成2组。赖诺普利组31例(男性16例,女性15例,年龄49a±s10a),给赖诺普利10~20mg,po,qd×4wk;氢氯噻嗪组25例(男性13例,女性12例,年龄50a±11a)给氢氯噻嗪25~50mg,po,tid×4wk。结果:赖诺普利组降压总有效率为94%与氢氯噻嗪组(92%)相仿(P>0.05)。赖诺普利组空腹血糖与胰岛素均有明显降低(P<0.01)。代表胰岛素敏感性1/(FPG×FINS)的试验显著提高的差别有非常显著的意义(P<0.01),而在氢氯噻嗪组则均无此反应。结论:赖诺普利具有提高EH病人胰岛素敏感性的作用。 相似文献
4.
目的探讨非洛地平(FM)与苯那普利(BE)对高血压病患者胰岛素抵抗(IR)及代谢的影响。方法测定122例高血压患者和38例正常血压作对照组(NS)的胰岛素敏感性指数(ISI)及血脂等水平,根据ISI值,把高血压分为高血压Ⅰ组(68例)与高血压醇Ⅱ组(54例),再分别把高血压I组和高血压Ⅱ组各随机分为非洛地平(FM)组与苯那普利(B)组,治疗8周后再测定ISI及血脂等变化。结果(1)Ⅰ组的ISI明显低于 Ⅱ组及阳组(P<0.05),而 Ⅱ组的ISI与NS组之间差异无显著意义(P>0.05);(2)两药治疗后血压均较治疗前显著降低(P<0.01);(3)Ⅰ组经两药治疗后ISI值均明显升高(P<0.01),Ⅱ组经两药治疗后ISI无显著变化(P>0.05(4)两药治疗后,Ⅰ组各项代谢指标均无显著变化(P>0.05)。结论FM与BE均可明显改善高血压Ⅰ组患者的IR,两药短期治疗对其它代谢指标无影响。 相似文献
5.
为探讨非胰岛素依赖型糖尿病(NIDDM)患者凝血及纤溶活性,采用ELISA双抗体夹心法测定了35例NIDDM患者的血浆D-二聚体。结果:NIDDM患者血浆D-二聚体水平为1.63mg/L±0.14mg/L),明显高于正常对照组(0.33mg/L±0.09mg/L)(P<0.05);有血管病变组D-二聚体为2.62mg/L±0.68mg/L,高于无血管病变组(0.69mg/L±0.68mg/L),差异有显著性(P<0.001);血浆D-二聚体与FBG、TC、TG相关分析表明D-二聚体与FBG、TG呈正相关(分别为r=0.58,P<0.001;r=0.035,P>0.2;n=14),与TC呈负相关(r=-0.045,P>0.2,n=14)。8例NIDDM患者治疗后血浆D-二聚体较治疗前显著降低,分别为1.11±0.81,3.65±1.22,P<0.05)。提示NIDDM患者体内存在高凝和继发纤溶活性亢进,血浆D-二聚体是反映NIDDM患者高凝和缺血性疾病的诊断、疗效观察的良好指标。 相似文献
6.
对Ⅰ期与Ⅱ期老年人高血压病(45例)和Ⅰ期与Ⅱ期非老年人高血压病(43例)应用培哚普利治疗并进行比较。结果表明两组在治疗后均有显著的降压效果(P<0.01),但是两组之间的降压总有效率和降压幅度均无显著性差异(P>0.05)。在治疗期间仅有的不良反应是干咳,其发生率在老年组为6.7%,非老年组则为7%(P>0.05)。提示培哚普利治疗Ⅰ期与Ⅱ期老年人高血压病的疗效较好而且安全。 相似文献
7.
血管紧张素转换酶基因插入/缺失多态性与冠心病关系的初步研究 总被引:1,自引:0,他引:1
目的:研究中国汉族人群血管紧张素转换酶(ACE)基因插入/缺失(I/D)多态性与冠心病的关系。方法:应用聚合酶链反应(PCR)检测40例冠心病和50例配伍对照组的血管紧张素转换酶(ACE)基因型,同时测血压、血脂、体重指数等指标。结果:冠心病组与对照组ACE基因型分布无显著性差异;DD型对DI型和II型优势比OR=1.52,95%可信区间为0.55~4.22,P〉0.05。结论:ACE基因I/D多 相似文献
8.
为了探讨Ⅱ型糖尿病患者动脉硬化的关键因素,我们观察了92例Ⅱ型糖尿病患者的体重指数、胰岛素面积、胰岛素敏感指数、血脂及并发冠心病和高血压病的发病率。结果显示:92例Ⅱ型糖尿病患者中胰岛素敏感指数与HDL-C/TC(r=-0.322,P<0.001)和LDL-C/HDL-C(r=0.346,P<0.001)相关较胰岛素面积(r=-0.238,P<0.05;r=0.240,P<0.05)和体重指数(r=-0.092,P>0.05;r=0.072,P>0.05)显著。且胰岛素抵抗组冠心病57.6%和高血压病36.4%的发病率也显著高于高胰岛素血症组48.8%、33.9%(P<0.05)和肥胖组48.1%、33.3%(P<0.05)。提示胰岛素抵抗是Ⅱ型糖尿病患者发生动脉硬化的关键因素之一。 相似文献
9.
10.
血管紧张素转换酶基因多态性与心肌梗关系的研究 总被引:2,自引:0,他引:2
本研究对80例心肌梗死患者和80例健康人的血管紧张素转换酶(ACE)活性;及ACE基因插入(I)/缺失(D)多态性进行了研究。结果表明MI组D基因频率50.3和DD基因型频率0.30显著高于对照组的0.31和0.10。MI组和正常人DD、DI、II基因型的血清ACE活性依次显著增高,因此ACE基因多态性可能是我国人MI发病的独立危险因素之一。 相似文献
11.
12.
13.
The prevention of histamine-induced gastric and duodenal ulceration in the guinea-pig has been examined using a series of undegraded and degraded carrageenans. Undegraded carrageenans were active at lower doses than degraded carrageenans. The high viscosity of the undegraded carrageenans in solution prevented their use in larger doses. Degradation of carrageenan without serious loss of sulphate, gives a product which allows the dose to be increased to an extent that its effect more than offsets the slight loss in activity caused by the degradation. No single feature of carrageenan structure can be related to anti-ulcer activity although degradation, and hence reduction of molecular size, generally reduces activity. Sulphate contents over 30% have little apparent effect on activity; κ-carrageenans were not consistently different in anti-ulcer activity from Λ-carrageenans. This contrasts with the antipeptic activity of carrageenans where κ-carrageenans are less active than their Λ-counter-parts. As with antipeptic activity, the degree of anti-ulcer activity is probably determined by a combination of structural features which includes molecular size and polyanionic properties. 相似文献
14.
15.
Larks and owls and health, wealth, and wisdom 总被引:1,自引:0,他引:1
16.
17.
《Journal of addictive diseases》2013,32(3):73-87
Depression and anxiety frequently coexist in patients with substance use disorders. This clinically-oriented article examiens the relationship between these conditions and emphasizes data showing that substances of abuse can cause signs and symptoms of both depression and anxiety. These substance-related syndromes appear to have a different course and prognosis than uncomplicated, independent anxiety and major depressive disorders, and clinicians should consider the role of alcohol and other drugs in all patients presenting with these complaints. The authors will also outline an approach for diagnosing and managing patients with the combination of a substance use and depressive or anxiety disorder. 相似文献
18.
19.
20.
Z J Witczak 《IDrugs : the investigational drugs journal》1998,1(1):30-31
The American Chemical Society Symposium "Glucosidase and fucosidase inhibitors" took place on 1 April 1998 and was organized by Professors Zbigniew J Witczak (UConn, School of Pharmacy, CT, USA), Kuniaki Tatsuta (Waseda University, Tokyo, Japan) and Waldemar Priebe, MD (Anderson Cancer Center, University of Texas, USA). Professor Witczak provided introductory remarks including the status of existing glucosidase inhibitors, and chaired the morning session, which consisted of six lectures. The symposium was well received, and was particularly attractive for those interested in networking, as attendance was about sixty. In addition, some participants and attendees presented posters on the subject during the regular poster session organized by the Division of Carbohydrate Chemistry. 相似文献